SCHEMBL30786144

SCHEMBL30786144

COc1ccc(CSc2cc(F)ccc2C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
PTPRG P23470 2/20 0.44
PTPRC P08575 1/20 0.44
ABL1 P00519 1/20 0.44
SRC P12931 1/20 0.44
PIK3CD O00329 1/20 0.44
USP2 O75604 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
DAO P14920 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2E1 P05181 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11826469 1.00 FFAR1 (0.47) FFAR1SMN1; SMN2NPC1RAB9APTPRG
SCHEMBL11817237 0.90 FFAR1 (0.47) FFAR1SMN1; SMN2NPC1RAB9APTPRG
SCHEMBL17080153 0.88 MAPT (0.46) FFAR1SMN1; SMN2NPC1RAB9AABL1
SCHEMBL30786181 0.88 MAPT (0.46) FFAR1SMN1; SMN2NPC1RAB9AABL1
SCHEMBL30786238 0.87 PTPRG (0.44) FFAR1SMN1; SMN2PTPRGPTPRCPIK3CD
SCHEMBL20644280 0.85 FFAR1 (0.57) FFAR1SMN1; SMN2NPC1RAB9APTPRG
SCHEMBL30786211 0.84 KMT2A (0.53) SMN1; SMN2NPC1RAB9AABL1SRC
SCHEMBL3495677 0.82 LMNA (0.44) FFAR1SMN1; SMN2NPC1RAB9AABL1
SCHEMBL6290570 0.81 RAB9A (0.67) FFAR1SMN1; SMN2NPC1RAB9APTPRG
SCHEMBL17080132 0.81 LMNA (0.48) SMN1; SMN2NPC1RAB9AABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 FFAR1 776/4885SMN1; SMN2 2289/4885NPC1 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.